What preclinical studies are for
Preclinical development is the bridge between a chosen candidate and the first human dose. Its core question is brutally simple: what dose can we give a person without an unacceptable chance of harm? To answer it, scientists run a battery of safety studies in animals (usually two species, one rodent and one non-rodent) plus a set of *in vitro* tests, while also nailing down how the drug is absorbed, distributed, metabolized, and cleared at the doses being used.
The pivotal safety studies must be run under Good Laboratory Practice (GLP) — a strict quality system that makes every result documented, reproducible, and auditable. A regulator will not let a molecule into humans on the strength of casual, unverifiable experiments.
From a safe animal dose to a safe human dose
The key output of toxicology is the no-observed-adverse-effect level (NOAEL): the highest dose at which no harmful effect is seen in the most sensitive animal species. From the NOAEL — corrected for body size and uncertainty — teams calculate a conservative *first human dose* far below it. The gap between the exposure that causes harm and the exposure you intend to use is the safety margin; a comfortable margin is what lets a first-in-human study go ahead.
The IND: the legal door to humans
When the preclinical package looks strong enough, the sponsor files an Investigational New Drug (IND) application (the name and details vary by region, but the idea is universal). It is a large dossier that bundles together everything a regulator needs to judge whether the proposed first-in-human trial is reasonable.
- Nonclinical data — the GLP toxicology, safety margins, genotoxicity and cardiac findings, plus animal pharmacology and PK.
- Manufacturing (CMC) — what the drug substance is, how it is made and controlled, and that it is pure and stable enough to dose people.
- Clinical protocol — the exact plan for the first-in-human study: starting dose, how it escalates, and the safety stopping rules.